Viral haemorrhagic fevers imported into non-endemic countries: Risk assessment and management

British Medical Bulletin

Volumn 95, Issue 1, 2010, Pages 193-225

  Bannister, Barbara ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

disease reservoirs; infection control; viral haemorrhagic fevers

Indexed keywords

FAVIPIRAVIR; RIBAVIRIN;

ABNORMAL DREAMING; AMINOTRANSFERASE BLOOD LEVEL; ARENAVIRUS; BAT; CLINICAL FEATURE; CRIMEAN CONGO HEMORRHAGIC FEVER; DIFFERENTIAL DIAGNOSIS; DISEASE CARRIER; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; ENDEMIC DISEASE; FLUID THERAPY; GEOGRAPHIC DISTRIBUTION; HEMOLYTIC ANEMIA; HUMAN; IMMUNOTHERAPY; INCUBATION TIME; INFECTION CONTROL; INFECTION RISK; INSOMNIA; JAUNDICE; LASSA FEVER; MARBURG HEMORRHAGIC FEVER; MARBURG VIRUS; MONKEY; NAIRO VIRUS; NAUSEA; NONHUMAN; PANCREATITIS; PATIENT CARE; PHYLOGENETIC TREE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; RURAL POPULATION; SIDE EFFECT; SOCIOECONOMICS; TRAVEL; VIRUS HEMORRHAGIC FEVER; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ANIMALS; DISEASE OUTBREAKS; DISEASE RESERVOIRS; DISEASE VECTORS; HEMORRHAGIC FEVERS, VIRAL; HUMANS; INFECTION CONTROL; RISK ASSESSMENT; WORLD HEALTH;

EID: 77956242682     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldq022     Document Type: Review

References (89)

1. Martini GA, Knauff HG, Schmidt HA et al. A hitherto unknown infectious disease contracted from monkeys. Marburg-virus disease. Ger Med Mon 1968;10:457-470
2. Emond RTD, Evans B, Bowen ETW et al. A case of Ebola virus infection. Br Med J 1977;583:541-544
3. Barry M, Russi M, Armstrong L et al. Brief report: treatment of a laboratory-acquired Sabia virus infection. N Engl J Med 1995;333:294-296
4. Armstrong LR, Dembry LM, Rainey PM et al. Management of a Sabia virus-infected patient in a US hospital. Infect Control Hosp Epidemiol 1999;20:176-182
5. Richards GA, Murphy S, Jobson R et al. Unexpected Ebola virus in a tertiary setting: clinical and epidemiological aspects. Crit Care Med 2000;28:240-244
6. Briese T, Paweska JT, McMullan LK et al. Genetic detection and characterisation of Lujo virus, a new haemorrhagic fever-associated Arenavirus from southern Africa. PLoS pathog 2009;5:e1000455.
7. Control of Substances Hazardous to Health The Control of Substances Hazardous to Health Regulations 2002. Approved Code of Practice and Guidance L5, 4th edn. HSE Books 2002. ISBN 0 7176 2534. http://www.hse.gov.uk/PUBNS/misc208. pdf (31 January 2010, date last accessed).
8. US Department of Health and Human Services. Centers for Disease Control and Prevention, National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL), 5th edn, 2007. http://www.cdc.gov/od/ohs/ biosfty/bmbl5/bmbl5toc.htm (31 January 2010, date last accessed).
9. US Department of Health and Human Services. Centers for Disease Control and Prevention, National Institutes of Health. Emergency Preparedness and Response: Bioterrorism Agents/ diseases, by Category. http://www.bt.cdc.gov/ agent/agentlist-category.asp (31 January 2010, date last accessed).
10. Health Protection Agency. Diseases A-Z, Deliberate and Accidental Releases. http://www.hpa.org.uk/HPA/Topics/InfectiousDiseases/InfectionsAZ/ 1197637044441/(31 January 2010, date last accessed).
11. Barquet N, Domingo P. Smallpox: the triumph over the most terrible of the ministers of death. Ann Intern Med 1997;127:635-642
12. Princes and Peasants. In: Hopkins DR (ed) Smallpox in History. University of Chicago Press 1983, ISBN-10:0226351769, ISBN-13978-0226351766.
13. Ranlet P. The British, the Indians and smallpox: what really happened at Fort Pitt in 1763? Pa Hist 2000;67:427-441
14. World Health Organisation. International Health Regulations 2005. http://www.who.int/ihr/en/ (31 January 2010, date last accessed).
15. Bannister B, Puro V, Fusco F et al., for the EUNID Working Group. Framework for the design and operation of high-level isolation units: consensus of the European Network of Infectious Diseases. Lancet Infect Dis 2009;9:45-56.
16. Department of Health and Human Services. Centers for Disease Control and Prevention. Interim Guidance for Managing Patients with Suspected Viral Haemorrhagic Fever in US Hospitals. http://www.cdc.gov.uk/ncidod/dhqp/bp-vhf- interimGuidance.html (31 January 2010, date last accessed).
17. Advisory Committee on Dangerous Pathogens. Management and Control of Viral Haemorrhagic Fevers. London: The Stationery Office, 1996.
18. Sullivan N, Zhi-Yong Y, Nabel GJ. Ebola virus pathogenesis: implications for vaccines and therapies. J Virol 2003;77:9733-9737
19. Prinz KC, Cardenas WB, Basler CF. Ebolavirus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol 2009;83: 3069-3077
20. Chang TH, Kubota T, Matsuoka M et al. Ebola Zaire blocks type 1 interferon production by exploiting the host SUMO modification machinery. PLoS Pathog 2009;5:e1000493.
21. Basler CF, Amarasinghe GK. Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res 2009;29:511-520
22. Warfield KL, Perkins JG, Swenson DL et al. Role of natural killer cells in innate protection against lethal Ebola virus infection. J Exp Med 2004;200:169-179
23. Schmitz H, Kohler B, Laue T et al. Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect 2002;4:43-50.
24. Mahanty S, Hutchinson K, Agarwal S et al. Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. J Immunol 2003;170:2797-2801
25. Hensley LE, Geisbert TW. The contribution of the endothelium to the development of coagulation disorders that characterize Ebola hemorrhagic fever in primates. Thromb Haemost 2005;94:254-261
26. Fischer-Hoch SP, Platt GS, Neild GH et al. Pathophysiology of shock and haemorrhage in a fulminating viral infection (Ebola). J Infect Dis 1985;152:887-894
27. Geisbert TW, Young HA, Jahrling PB et al. Inflammatory responses in Ebola virus-infected patients. Am J Pathol 2003;163:2371-2382
28. Baize S, Leroy EM, Georges AJ et al. Pathogenesis of Ebola hemorrhagic fever in primate models: evidence that hemorrhage is not a direct effect of virus-induced cytolysis of endothelial cells. Clin Exp Immunol 2002;128:163-168
29. Shepherd AJ, Swanepoel R, Leman PA et al. Field and laboratory investigation of Crimean-Congo haemorrhagic fever virus (Nairovirus, family Bunyaviridae) infection in birds. Trans Roy Soc Trop Med Hyg 1987;81:1004-1007
30. Zeller HG, Cornet JP, Camicas J L. Experimental transmission of Crimean-Congo hemorrhagic fever virus by West African wild groundfeeding birds to Hyalomma marginatum rufipes ticks. Am J Trop Med Hyg 1994;50:676-681
31. Wolfel R, Paweska JT, Petersen N et al.Virus detection and monitoring of viral load in Crimean-Congo hemorrhagic fever virus patients Emerg Infect Dis [serial on the Internet]. 2007. http://www.cdc.gov/EID/content/13/7Z1097.htm (31 January 2010, date last accessed).
32. Deyde VM, Khristova ML, Rollin P et al. Crimean-Congo haemorrhagic fever virus and global diversity. J Virol 2006;80:8834-8842
33. Christova I, Di Caro A, Papa A et al. Crimen-Congo haemorrhagic fever, Southwestern Bulgaria. Emerg Infect Dis 2009;15:983-985
34. Karti SS, Odabasi Z, Korten A et al. Crimean Congo haemorrhagic fever in Turkey. EID 2004;10:1379-1384
35. Ergönül Ö, Celikbas A, Dokuzoguz B et al. The chacteristics of Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and the impact of oral ribavirin therapy. Clin Infect Dis 2004;39:285-289
36. Gunes T, Engin A, Poyraz O et al. Crimean-Congo hemorrhagic fever virus in high-risk population, TurkeyEmerg Infect Dis [serial on the Internet]. 2009 March. http://www.cdc.gov/EID/content/15/3/461.htm
37. Papa A, Bino S, Llagami A et al. Crimean-Congo haemorrhagic fever in Albania. Eur J Clin Microbiol Infect Dis 2002;21:603-606
38. Chinikar S, Ghiasi SM, Hewson R et al. Crimean-Congo haemorrhagic fever in Iran and neighboring countries. J Clin Virol [Epub ahead of print] PMID 20006541.
39. Mardani M, Keshtkar-Jahromi M, Ataie B et al. Crimean-Congo hemorrhagic fever virus as a nosocomial pathogen in Iran. Am J Trop Med Hyg 2009;81:675-678
40. Celikbas A, Ergönül Ö, Dokuzoguz B et al. Crimean Congo hemorrhagic fever infection simulating acute appendicitis. J Infect 2005;50:363-365
41. Swanepoel R, Gill DE, Shepherd AJ et al. The clinical pathology of Crimean-Congo hemorrhagic fever. Rev Infect Dis 1989;11(Suppl. 4):S794-S800.
42. Duh D, Saksida A, Petrovec M et al. Viral Load as Predictor of Crimean-Congo Hemorrhagic Fever Outcome. Emerg Infect Dis 2007;13. www.cdc.gov/eid.
43. Bodur H, Akinci E, Ongiirii P et al. Detection of Crimean-Congo hemorrhagic fever virus genome in saliva and urine. Int J Infect Dis 2009 [Epub ahead of print].
44. Watts DM, Ussery MA, Nash D et al. "Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin". Am J Trop Med Hyg 1989;41:581-585
45. Fischer-Hoch SP, Khan JA, Rehman S et al. Crimean-Congo haemorrhagic fever treated with oral ribavirin. Lancet 1995;346:472-475
46. Izadi S, Salehi M. Evaluation of the efficacy of ribavirin therapy on survival of Crimean-Congo haemorrhagic fever patients: a casecontrol study. Jpn J Infect Dis 2009;62:11-15
47. Kunchev A, Kojouharova M. Probable cases of Crimean-Congo haemorrhagic fever in Bulgaria: a preliminary report. Euro Surveill 2008;13:pii=18845. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18845 (21 January 2010, date last accessed).
48. Flick R, Flick K, Feldmann H et al. Reverse Genetics for Crimean-Congo hemorrhagic fever Virus. J Virol 2003;77:5997-6006. doi: 10.1128/JVI.77.10.5997- 6006.2003.
49. Juan C, de la Torre. Reverse genetics approaches to combat pathogenic arenaviruses. Antiviral Res 2008;80:239-250
50. Martini G, Siegert R (eds). Marburg Virus Disease. Vienna and New York: Springer Verlag, 1971.
51. Bausch DG, Borchert M, Grein T et al. Risk factors for Marburg haemorrhagic fever, Democratic Republic of the Congo. Emerg Infect Dis 2003;12:1531-1537
52. Borchert M, Mulangu S, Swanepoel Libande ML et al. Serosurvey on household contacts of Marburg haemorrhagic fever patients. Emerg Infect Dis 2006;12:433-439
53. Marburg haemorrhagic fever. Wkly Epidemiol REc 2007;82:317.
54. Uganda-update. Ligon BL. Outbreak of Marburg haemorrhagic fever in Angola: a review of the history of the disease and its biological aspects. Semin Paediatr Infect Dis 2005;16:219-224
55. Department of Health and Human Services Centers for Disease Control and Prevention (Atlanta). Mortality and Morbidity Weekly Report. 2009 Imported case of Marburg haemor - rhagic fever - Colorado. 2008;58:1377-1381
56. [No authors listed]. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/ International Study Team. Bull World Health Organ 1978; 56: 247-270.
57. Gear JS, Cassel GA, Gear AJ et al. Outbreak of Marburg virus disease in Johannesburg. Br Med J 1975;4:489-493
58. Kiley MP, Cox N, Elliott LH et al. Physicochemical properties of Marburg virus: evidence for three distinct virus strains and their relationship to Ebola virus. J Gen Virol 1988;69: 1957-1967
59. Mason C. The strains of Ebola. CMAJ 2008;178:1266-1267
60. Towner J, Sealy TK, Khristova ML et al. Newly discovered Ebola virus associated with haemorrhagic fever outbreak in Uganda. PLoS Pathogens. 2008;4:e100212.
61. Jahrling PB, Geisbert TW, Dalgard DW et al. Preliminary report: isolation of Ebola virus from monkeys imported to USA. Lancet 1990;335:502-505
62. Miranda ME, Kzaizek TG, Retuya TJ et al. Epidemiology of Ebola (subtype Reston) in the Philippines. J Infect Dis 179(Suppl. 1):S115-S119.
63. WHO. Weekly Epidemiol Review 84 Philippines: Ebola Reston in pigs and humans, 2009,49.
64. Towner JS, Amman BR, Sealy TK et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog 2009;5:e1000536.
65. Pourrut X, Souris M, Towner J et al. Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations and a high seroprevalence of both viruses in Rousettus aegypticus. BMC Inf Dis 2009;9:159-169
66. Colebunders R, Tshomba A, Kerkhove V et al. Marburg haemorrhagic fever in Durba and Watsa, Democratic Republic of the Congo: clinical documentation, features of the illness and treatment. J Infect Dis 2007;196(Suppl. 2):S148-S153. Borchert M, Mulangu S, Swanepoel R, Libande ML, Tshomba A, et al.
67. Leroy EM, Baize S, Volchkov VE et al. Serosurvey of household contacts. Human asymptomatic Ebola infection and strong inflammatory response. Lancet 2000;355:2210-2215
68. Kuming BS, Kokoris N. Uveal involvement in Marburg virus disease. Br J Ophthalmol 1977;61:265-266
69. Saijo M, Niikura M, Ikegami T et al. Laboratory diagnostic systems for Ebola and Marburg hemorrhagic fevers developed with recombinant proteins. Clin Vaccine Immunol 2006;13:444-451
70. McKinney MD, Moon SJ, Kulesh DA et al. Detection of viral RNA from paraffin-embedded tissues after prolonged formalin fixation. J Clin Virol 2009;44:31-42.
71. Feldmann H, Jones SM, Daddario-DiCaprio KM et al. Effective post-exposure treatment of Ebola infection. PLoS Pathog 2007;3:e2.
72. Tuffs A. Experimental vaccine may have saved Hanburg scientist from Ebola fever. BMJ 2009;338:b1223.
73. Yang C, Ye L, Compans RW. Protection against filovirus infection: virus-like particle vaccines. Expert Rev Vaccines 2008;7:333-344
74. Ogbu O, Ajuluchukwu E, Uneke CJ. Lassa fever in the West African sub-region: an overview. J Vector Borne Dis 2007;44:1-11.
75. Khan SH, Goba A, Chu M et al. New opportunities for field research on the pathogenensis and treatment of Lassa fever. Antivral Res 2008;78:103-115
76. Gunther S, Emmerich P, Laue T et al. Imported Lassa fever in Germany: molecular characterisation of a new Lassa virus strain. Emerg Inf Dis 2000;6:466-476
77. Emmerich P, Gunther S, Scmitz H. Strain-specific antibody to Lassa virus in the local population of West Africa. J Clin Virol 2008;42:40-44
78. Delagado S, Erikson BR, Agudo R et al. Chapare virus, a newly discovered arenavirus isolated from a fatal haemorrhagic fever case in Bolivia. PLoS Pathog 2008;4:e1000047.
79. McCormick JB, King IJ, Webb PA et al. A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis 1987;155:445-455
80. Lenz O. Lassa virus. Crit Rev Clin Lab Sci 2004;41:339-90.
81. J Infect Dis 1987;155(3): 445-455
82. McCormick JB, King IJ, Webb PA et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986;314:20-26
83. Schmitz H, Kohler B, Laue T et al. Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microb Infect 2002;4:43-50.
84. Gowen B, Smee DF, Wong M-H et al. Treatment of late stage disease in a model of arenaviral haemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS ONE 3:e3725.
85. Enria DA, Briggiler AM, Sanchez Z. Treatment of Argentine hemorrhagic fever. Antiviral Res 2008;78:132-139 [Epub 20 2007 November].
86. AHF Study Group. Maiztegui JI, McKee KT Jr, Barrera Oro JG et al. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. J Infect Dis 1998;177:277-283
87. Cooper CB, Gransden WR, Webster M et al. A case of Lassa fever: experience at St Thomass Hospital. Br Med J 1982;285:1003-1005
88. Boumandouki P, Formenty P, Epelboin A et al. Clinical management of patients and deceased during the Ebola outbreak from October to December 2003 in Republic of Congo[Article in French; abstract in English]. Bull Soc Pathol Exot 2005; 98.
89. Dowell SF, Mukunu R, Ksiazek TG, Khan AS, Rollin PE, Peters CJ. Transmission of Ebola hemorrhagic fever: a study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999; 179 (Suppl. 1):S87-91.